Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial.

meplazumab - Jiangsu Pacific Meinuoke Biopharmaceutical, Air Force Medical University

http://www.ncbi.nlm.nih.gov/pubmed/36717539

Jan 31, 2023